Sagimet Biosciences INC

Sagimet Biosciences reports the resignation of director Tim Walbert and the successful election of four Class III directors at its 2026 Annual Meeting.

Sagimet Biosciences announced first quarter 2026 financial results, highlighting a $175 million equity financing and plans to initiate a Phase 3 acne trial in the second half of 2026.

Sagimet Biosciences Inc. announced the pricing of an underwritten public offering of 29,166,700 shares of its common stock at $6.00 per share, expecting net proceeds of $164.5 million.

Sagimet Biosciences Inc. provided an update on its FASN inhibitor programs, denifanstat and TVB-3567, highlighting clinical trial progress and future development plans for acne and MASH indications.

Sagimet Biosciences provides updates on its lead drug denifanstat for acne and MASH, and its second FASN inhibitor TVB-3567, with key clinical trial timelines and strategic financial planning.

Sagimet Biosciences Inc. reported the retirement of its Chief Medical Officer, Eduardo Martins, M.D., D.Phil., effective April 20, 2026, and announced the appointment of Andreas Grauer, M.D. to the same role.

Sagimet Biosciences reports a significant decrease in R&D expenses for Q1 2026, improved cash flow from investing activities, and sufficient liquidity for the next 12 months following a substantial capital raise.

Sagimet Biosciences reported a reduced net loss in Q3 2025, driven by lower R&D expenses, while advancing its denifanstat and TVB-3567 clinical programs for MASH and acne.

Sagimet Biosciences reports increased losses and cash burn in Q2 2025, alongside significant clinical progress for denifanstat in MASH and acne, and the initiation of a new Phase 1 trial for TVB-3567.

Sagimet Biosciences' Q1 2025 report highlights increased R&D spending, progress in clinical trials, and ongoing efforts to secure funding for Phase 3 trials.

Sagimet Biosciences announced its third quarter 2024 financial results, highlighted by progress in its Phase 3 clinical program for denifanstat and a Breakthrough Therapy designation from the FDA.

Sagimet Biosciences' second quarter 2024 report highlights increased R&D spending, positive clinical trial data, and a strengthened financial position.

Sagimet Biosciences' 10-K filing highlights the company's progress in developing denifanstat for MASH, including positive Phase 2b results and the initiation of Phase 3 clinical trials.

Sagimet Biosciences' 10-K filing outlines the company's capital stock structure, registration rights, anti-takeover provisions, and compliance with securities regulations.

David Happel, President & CEO and a Director of Sagimet Biosciences Inc., sold 64,051 shares of common stock on July 20, 2026 for $7.76 per share.

Elizabeth Rozek, Chief Legal & Admin. Officer of Sagimet Biosciences Inc., sold 10,545 shares of common stock on July 20, 2026 for $7.76 per share.

George Kemble, a Director of Sagimet Biosciences Inc., sold 18,844 shares of common stock on July 20, 2026 for $7.46 per share.

Director Beth Seidenberg acquired stock options for 39,567 shares of Sagimet Biosciences Inc. (SGMT) on June 12, 2026, with an exercise price of $6.48.

Paul W. Hoelscher, a Director at Sagimet Biosciences Inc., acquired stock options for 39,567 shares of Series A Common Stock.

Jennifer Jarrett, a Director at Sagimet Biosciences Inc., acquired stock options for 39,567 shares.

Sagimet Biosciences Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 12, 2026, to be held virtually.

Sagimet Biosciences prepares for its 2025 Annual Meeting with director elections and ratification of its accounting firm, while also navigating board restructuring.

Sagimet Biosciences Inc. will hold its annual stockholder meeting on June 5, 2024, to elect Class I directors and ratify the appointment of Deloitte & Touche LLP as its independent auditor.

Sagimet Biosciences announces its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024, featuring proposals for director elections and ratification of the company's independent accounting firm.

Sagimet Biosciences has filed an amendment to its S-1 registration statement for a proposed offering of 9,000,000 shares of Series A common stock.

Sagimet Biosciences plans to offer 9 million shares of Series A common stock following positive topline results from its FASCINATE-2 Phase 2b clinical trial for NASH treatment.

BlackRock, Inc. has reported beneficial ownership of 7.8% of Sagimet Biosciences Inc.'s Class A Stock as of June 30, 2026.

KPCB Pandemic and Bio Defense Fund, LLC and KPCB PBD Associates, LLC have filed an early exit Schedule 13G, reporting zero beneficial ownership in Sagimet Biosciences Inc. due to their planned termination.

Woodline Partners LP has filed an amended Schedule 13G, reporting a 4.8% beneficial ownership stake in Sagimet Biosciences Inc.'s Series A Common Stock.

Point72 Asset Management and its affiliates have reported a complete divestment of their Series A Common Stock in Sagimet Biosciences Inc., holding 0% as of June 30, 2025.

Woodline Partners LP has reported a significant 8.3% beneficial ownership stake in Sagimet Biosciences Inc.'s Series A Common Stock.

AP11 Limited and Ascletis Pharma Inc. have filed an amendment to their Schedule 13G, reporting a passive beneficial ownership of 4.9% in Sagimet Biosciences Inc.'s Series A common stock.